Shots:

• The P-III KEYNOTE-177 study involves assessing of Keytruda as monothx. vs SOC CT (mFOLFOX6/ FOLFIRI- with/out bevacizumab/ cetuximab) as a 1L treatment in 308 patients with MSI-H or dMMR advanced colorectal cancer
• The P-III KEYNOTE-177 study resulted in meeting its one of its dual 1EPs i.e. demonstrated significant improvement in PFS. Following the DMC’s recommendation- the study will continue without changes to evaluate OS- the other dual 1EP
• Keytruda is an anti-PD-1 therapy- act by blocking the interaction between PD-1 and its ligands- PD-L1 and PD-L2 thus activates T lymphocytes affecting both tumor and healthy cells and has received FDA’s approval as the first therapy for use on a biomarker- regardless of tumor type- in prior treated patients with MSI-H or dMMR solid tumors in May’2017

Click here ­to­ read full press release/ article

Ref: Merck & Co. | Image: Lucky Step